PMCB
Silverman Joshua, PMCB's CEO, spent $33.3K of their own money on 40,000 shares at $1, growing their stake 11%.
+$33.3K
40,000 sh @ $1
PMCB
PharmaCyte Biotech, Inc.
SEC CIK 1157075
$0.7610
+7.6% · 90 days
90-day buys
$0
0 open-market
90-day sells
$0
0 open-market
Net insider flow
+$0
Net buying
Filings shown
16
Most recent
Advertisement
At a glance
Insiders at PMCB have made no open-market trades in the last 90 days — the activity below is grants, option exercises, and other routine filings.
Largest recent trade: Silverman Joshua, PMCB's CEO, spent $33.3K of their own money on 40,000 shares at $1, growing their stake 11%.
Most active filer: Silverman Joshua, with 5 transactions among the recent filings shown.
Insider transaction history
Form 4 filings for PMCB, newest firstPMCB
Schechter Jonathan, PMCB's Director, spent $16.9K of their own money on 20,000 shares at $1, growing their stake 12%.
+$16.9K
20,000 sh @ $1
PMCB
Silverman Joshua, PMCB's CEO, spent $23.7K of their own money on 30,000 shares at $1, growing their stake 9%.
+$23.7K
30,000 sh @ $1
PMCB
Schechter Jonathan, PMCB's Director, spent $15.8K of their own money on 20,000 shares at $1, growing their stake 13%.
+$15.8K
20,000 sh @ $1
PMCB
Silverman Joshua, PMCB's CEO, spent $23.5K of their own money on 30,000 shares at $1, growing their stake 9%.
+$23.5K
30,000 sh @ $1
Advertisement
PMCB
Schechter Jonathan, PMCB's Director, spent $15.6K of their own money on 20,000 shares at $1, growing their stake 15%.
+$15.6K
20,000 sh @ $1
PMCB
+$0
75,000 sh
PMCB
−$34.4K
33,750 sh @ $1
PMCB
+$0
37,500 sh
PMCB
−$17.2K
16,875 sh @ $1
PMCB
+$0
575,000 sh
PMCB
−$263.9K
258,750 sh @ $1
PMCB
+$0
150,000 sh
PMCB
−$68.9K
67,500 sh @ $1
PMCB
+$0
37,500 sh
PMCB
−$17.2K
16,875 sh @ $1
Advertisement
About PMCB insider activity
This page tracks every recent Form 4 filed for PharmaCyte Biotech, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.
The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.
Frequently asked questions
How often is PMCB insider data updated?
Continuously. We read from SEC EDGAR, so new Form 4 filings for PharmaCyte Biotech, Inc. usually appear here within minutes of being accepted by the SEC.
What does "net insider flow" mean?
It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.
Why do some rows show grants or option exercises instead of buys?
Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.
Is this investment advice?
No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.